1. Home
  2. SPRO vs SPAI Comparison

SPRO vs SPAI Comparison

Compare SPRO & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • SPAI
  • Stock Information
  • Founded
  • SPRO 2013
  • SPAI 2021
  • Country
  • SPRO United States
  • SPAI United States
  • Employees
  • SPRO N/A
  • SPAI N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • SPAI Industrial Specialties
  • Sector
  • SPRO Health Care
  • SPAI Health Care
  • Exchange
  • SPRO Nasdaq
  • SPAI Nasdaq
  • Market Cap
  • SPRO 128.9M
  • SPAI 139.4M
  • IPO Year
  • SPRO 2017
  • SPAI 2024
  • Fundamental
  • Price
  • SPRO $2.33
  • SPAI $6.14
  • Analyst Decision
  • SPRO Buy
  • SPAI Strong Buy
  • Analyst Count
  • SPRO 4
  • SPAI 2
  • Target Price
  • SPRO $5.00
  • SPAI $10.50
  • AVG Volume (30 Days)
  • SPRO 1.2M
  • SPAI 506.2K
  • Earning Date
  • SPRO 11-13-2025
  • SPAI 11-13-2025
  • Dividend Yield
  • SPRO N/A
  • SPAI N/A
  • EPS Growth
  • SPRO N/A
  • SPAI N/A
  • EPS
  • SPRO N/A
  • SPAI N/A
  • Revenue
  • SPRO $48,576,000.00
  • SPAI $1,496,091.00
  • Revenue This Year
  • SPRO N/A
  • SPAI N/A
  • Revenue Next Year
  • SPRO N/A
  • SPAI $538.54
  • P/E Ratio
  • SPRO N/A
  • SPAI N/A
  • Revenue Growth
  • SPRO N/A
  • SPAI 7.49
  • 52 Week Low
  • SPRO $0.51
  • SPAI $1.47
  • 52 Week High
  • SPRO $3.22
  • SPAI $9.16
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 56.08
  • SPAI 43.34
  • Support Level
  • SPRO $2.16
  • SPAI $6.03
  • Resistance Level
  • SPRO $2.42
  • SPAI $7.50
  • Average True Range (ATR)
  • SPRO 0.12
  • SPAI 0.91
  • MACD
  • SPRO -0.00
  • SPAI -0.17
  • Stochastic Oscillator
  • SPRO 46.85
  • SPAI 4.29

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SPAI Safe Pro Group Inc. Common Stock

Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.

Share on Social Networks: